Chris German - Oncorus Controller
| ONCRDelisted Stock | USD 0.04 0.01 14.71% |
Insider
Chris German is Controller of Oncorus
| Phone | 857 320 6400 |
| Web | https://www.oncorus.com |
Oncorus Management Efficiency
The company has return on total asset (ROA) of (0.3224) % which means that it has lost $0.3224 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2456) %, meaning that it created substantial loss on money invested by shareholders. Oncorus' management efficiency ratios could be used to measure how well Oncorus manages its routine affairs as well as how well it operates its assets and liabilities.Oncorus currently holds 70.65 M in liabilities with Debt to Equity (D/E) ratio of 0.72, which is about average as compared to similar companies. Oncorus has a current ratio of 6.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Oncorus' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Jan Pinkas | Pyxis Oncology | N/A | |
| RPh PharmD | Elevation Oncology | 40 | |
| David Dornan | Elevation Oncology | 46 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Marcel CPA | Altamira Therapeutics | 66 | |
| MBA MBA | Pyxis Oncology | 51 | |
| Samuel MD | Altamira Therapeutics | 71 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| Martina BS | Pyxis Oncology | 59 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| MBA JD | Cardio Diagnostics Holdings | 60 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Balu Balasubramanian | Pyxis Oncology | N/A | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| Covadonga Paeda | Altamira Therapeutics | N/A | |
| Pamela MBA | Pyxis Oncology | 62 | |
| Valerie MD | Elevation Oncology | 46 | |
Management Performance
| Return On Equity | -1.25 | |||
| Return On Asset | -0.32 |
Oncorus Leadership Team
Elected by the shareholders, the Oncorus' board of directors comprises two types of representatives: Oncorus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncorus. The board's role is to monitor Oncorus' management team and ensure that shareholders' interests are well served. Oncorus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncorus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard MBA, Chief CFO | ||
| Brian Shea, Director Sec | ||
| Chris German, Controller | ||
| Stephen Harbin, COO Staff | ||
| Mitchell Finer, NonEx Chairman | ||
| John MD, Chief Officer |
Oncorus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncorus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.25 | |||
| Return On Asset | -0.32 | |||
| Current Valuation | 25.71 M | |||
| Shares Outstanding | 26.09 M | |||
| Shares Owned By Insiders | 12.69 % | |||
| Shares Owned By Institutions | 55.29 % | |||
| Number Of Shares Shorted | 447.72 K | |||
| Price To Book | 0.13 X | |||
| EBITDA | (75.42 M) | |||
| Net Income | (77.42 M) |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Oncorus Stock
If you are still planning to invest in Oncorus check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncorus' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |